Literature DB >> 26577257

Fibrin clot structure in patients with congenital dysfibrinogenaemia.

A Casini1, C Duval2, X Pan2, V Tintillier3, C Biron-Andreani4, R A S Ariëns2.   

Abstract

The clinical phenotype of patients with congenital dysfibrinogenaemia is highly heterogeneous, from absence of symptoms to mild bleeding, or thrombosis. A few mutations are associated with a specific phenotype, but generally the clinical course is not predictable. We investigated whether fibrin clot properties are correlated with the patient's phenotype and/or genotype. Ex vivo plasma fibrin clot characteristics, including turbidity, fibrinolysis, clot permeability and fibrin fibre density assessed by laser scanner confocal microscopy were investigated in 24 genotyped patients with congenital dysfibrinogenaemia compared to normal pool plasma. Compared to normal pool plasma, the patients were characterised by slower fibrin polymerisation (lag time, 345.10 ± 22.98 vs. 166.00s), thinner fibrin fibres (maximum absorbance, 0.15 ± 0.01 vs. 0.31), prolonged clot lysis time (23.72 ± 0.97 vs. 20.32 min) and larger clot pore size (21.5×10(-9) ± 4.48×10(-9) vs. 7.96×10(-9)cm(2)). Laser scanning confocal microscopy images confirmed disorganised fibrin networks in all patients. Patients with tendency to bleed showed an increased permeability compared to asymptomatic patients (p=0.01) and to patients with a thrombotic history (p=0.02) while patients with thrombotic history had a tendency to have a prolonged clot lysis time. Fibrin clot properties were similar among hotspot mutations. Further studies including a larger number of patients are needed to evaluate whether analysis of permeability and clot lysis time may help to distinguish the clinical phenotype in these patients and to assess differences according to the genotype.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Congenital dysfibrinogenaemia; Fibrinolysis; Laser scanner confocal microscopy; Mutation; Permeability

Mesh:

Substances:

Year:  2015        PMID: 26577257     DOI: 10.1016/j.thromres.2015.11.008

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

2.  Thrombin generation and fibrin clot structure after vitamin D supplementation.

Authors:  Marc Blondon; Emmanuel Biver; Olivia Braillard; Marc Righini; Pierre Fontana; Alessandro Casini
Journal:  Endocr Connect       Date:  2019-11-01       Impact factor: 3.335

3.  Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.

Authors:  Linda Labberton; Ellinor Kenne; Andy T Long; Katrin F Nickel; Antonio Di Gennaro; Rachel A Rigg; James S Hernandez; Lynn Butler; Coen Maas; Evi X Stavrou; Thomas Renné
Journal:  Nat Commun       Date:  2016-09-06       Impact factor: 14.919

4.  Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors.

Authors:  Julia S Gauer; Nicoletta Riva; Eden M Page; Helen Philippou; Michael Makris; Alex Gatt; Robert A S Ariëns
Journal:  Res Pract Thromb Haemost       Date:  2020-10-25

Review 5.  Mechanisms of fibrinolysis resistance and potential targets for thrombolysis in acute ischaemic stroke: lessons from retrieved stroke emboli.

Authors:  Waleed Brinjikji; Oana Madalina Mereuta; Daying Dai; David F Kallmes; Luis Savastano; Yang Liu; Shahid M Nimjee; Raul G Nogueira; Mehdi Abbasi; Ramanathan Kadirvel
Journal:  Stroke Vasc Neurol       Date:  2021-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.